Saccharomyces boulardii is unique probiotic and biotherapeutic yeast, known to survive in gastric acidity and it is not adversely affected or inhibited by antibiotics or does not alter or adversely affect the normal microbiota. S. boulardii has been utilized worldwide as a probiotic supplement to support gastrointestinal health. The multiple mechanisms of action of S. boulardii and its properties may explain its efficacy and beneficial effects in acute and chronic gastrointestinal diseases that have been confirmed by clinical trials. Caution should be taken in patients with risk factors for adverse events. Its potential application in various dairy foods could offer an alternative probiotic product to people suffering from antibiotic-associated diarrhea. This review discusses the evidence for efficacy and safety of S. boulardii as a probiotic for the prevention and therapy of gastrointestinal disorders in humans.
INTRODUCTION

Saccharomyces boulardii as a probiotic yeast
"Probiotics" were first conceptualized at the start of the 20th century by Elie Metchnikoff's discovery of the immunological benefit of lactic acid bacteria in fermented milk. Today, lactobacilli and bifidobacteria are among the most important and widely consumed probiotics (Table 1) . Species from other bacterial genera such as Escherichia, Bacillus and Enterococcus have also been used, but there are concerns surrounding the safety of such probiotics as these genera contain opportunistic pathogenic species, particularly Enterococcus (FAO/WHO, 2002). Few non-bacterial microorganisms such as yeasts, Saccharomyces boulardii and some Saccharomyces cerevisiae strains, are also studied or commercialized as probiotics (Holzapfel et al., 2001 ). It is important to mention that for a microorganism to be considered probiotic, it must survive passage through the stomach and maintain its viability and metabolic activity in the intestine (van der Aa Kühle et al., 2005) . Native inhabitants of the human or animal gastrointestinal tract, such as lactobacilli and bifidobacteria, are considered to be probiotic, but often display low stress tolerance, which reduces their viability in probiotic applications. The word "probiotic" comes from Greek and means "for life" (Hamilton-Miller, 2004) . Over the years, the term "probiotic" has been given several definitions. FAO/WHO (2002) stated that probiotics are "live microorganisms which when administered in adequate amounts confer a health benefit on the host". Recent document represented the conclusions of the International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus meeting on the appropriate use and scope of the term probiotic (Hill et al., 2014) . (Figure 1 ) is a strain of yeast, first isolated from lychee fruit in Indochina and reported in the literature in 1920 by a French biologist Henri Boulard. Since 1980s, a series of studies on S. boulardii have been conducted to determine the benefits and mechanism of activity of this microorganism. In addition, the yeast S. boulardii can be separated from other strains of S. cerevisiae with respect to its probiotic potential and its inability to use the products of galactose and ascospores. For these reasons, some researchers believe that the probiotic yeast should be considered as its type.
S. boulardii
Several studies specifically with micro satellite polymorphism showed a clear pattern on the basis of which it is possible to distinguish between S. boulardii and S. cerevisiae, there are also RAPD (Rapid Amplified Polymorphic DNA) and electrophoretic karyotypes analysis (Mc Farland et al., 2010) . Due to the conflicting research results in practice currently uses the name S. boulardii (nom. nud). The term is mainly used for species that are similar to known species, but not yet taxonomically classified.
These strains are in the process of obtaining scientific name, until a detailed description, which is in line with current standards nomenclature (ICZN, 2014).
S. boulardii has an unusually high optimal growth temperature of 37 ºC. It is a unique probiotic, known to survive gastric acidity and it is not adversely affected or inhibited by antibiotics or does not alter or adversely affect the normal microbiota in the bowel ( S. boulardii secretes enzymatic proteins, including a protease that degrades C. difficile toxins and a phosphatase that inactivates endotoxin such as the lipopolysaccharide produced by E. coli. S. boulardii also promotes production of disaccharidases such as lactase, sucrase, maltase, and N-aminopeptidase in the brush border allowing increased carbohydrate degradation and absorption in patients with diarrhea, and restores normal levels of short chain fatty acids in the colon which are necessary for absorption of water and electrolytes (Marcia, 2009 ).
While there is quickly increasing information on the influence of S. boulardii on the bacterial origin diseases the interaction between S. boulardii and Candida spp. are much less studied. Further, S. boulardii is naturally resistant to antibiotics and therefore is not affected by antibiotics and sulfamide. It is considered as an effective means for the prevention and treatment of diarrhea, due to the imbalance of the intestinal microbiota in patients with long-term antibiotic treatment, whereas many other probiotics do not have this ability (Qamar et al., 2001 ).
Bacterial probiotics have considerable potential for preventive and therapeutic applications in AAD. However, it is important to note that the effects of any bacteria are strain specific and the efficacy demonstrated for a single given bacterial strain cannot be extrapolated to other probiotic organisms.
A variety of bacteria have been studied to explore their probiotic effect, Lactobacillus rhamnosus GG is a specific bacterial strain which demonstrates a probiotic effect in the prevention of AAD. Other strains of L. rhamnosus species may not have this effect, and likewise other species in the genus of Lactobacillus may not act as probiotics. This is because individual strains exhibit different specific characterristics, such as resistance to gastric acid and bile, ability to colonize the mucosa, and antimicrobial activity (Hickson, 2011 ). The choice of a high-quality probiotic product is one of the most important factors that determine efficacy of the probiotic. The stability of the probiotic product may significantly affect its potency over time.
Lyophilized products are stable at room temperature, have the advantage of portability and maintain high viability counts over prolonged periods (Graff et al., 2008 Therefore, the mechanisms of this yeast's probiotic action need to be identified, and any potential for virulence must be fully investigated.
CONCLUSIONS
In conclusion, using S. boulardii in the prevention and/or the treatment of diarrhea have been widely investigated and demonstrated.
However, new data and further experimental studies should permit to better elucidate the mechanisms of action of the yeast and suggest new therapeutic applications. Although the administration of S. boulardii can be associated with fungemia, no adverse effects were observed in any of the clinical trials.
Caution should be taken in patients with risk factors for adverse events, such as immunocompromised patients.
Dairy foods can serve as the ideal system for delivery of probiotics to the human gastrointestinal tract (Andrade Araújo et al., 2012), due to provision of a favorable environment that promotes the growth and enhances the viability of these microorganisms.
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